Conversely, in osteoarthritis (OA) patients, baricitinib suppresses NF-κB phosphorylation, leading to reduced p-p65 levels, attenuated inflammation, and delayed joint destruction(84). The gene discussed is NFKB1; the disease is osteoarthritis.